Asieris Pharma Announces Positive Data from Bladder Cancer Drug Trial

Asieris Pharmaceuticals, located in Taizhou City and also known as Jiangsu Yahong, presented positive preliminary results from its ongoing Phase II clinical trial of APL-1202, an oral MetAP2 inhibitor, in patients with bladder cancer. Asieris is focused on making breakthroughs in cancer treatment by repurposing available drugs. APL-1202 is nitroxoline, a wide spectrum antibiotic with an anti-angiogenesis effect that has been used in several countries for about fifty years. Asieris presented the results at the European Association of Urology (EAU) 2016 Congress in Munich, Germany. More details.... Share this with colleagues: // //